ZA979235B - The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors - Google Patents
The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitorsInfo
- Publication number
- ZA979235B ZA979235B ZA979235A ZA979235A ZA979235B ZA 979235 B ZA979235 B ZA 979235B ZA 979235 A ZA979235 A ZA 979235A ZA 979235 A ZA979235 A ZA 979235A ZA 979235 B ZA979235 B ZA 979235B
- Authority
- ZA
- South Africa
- Prior art keywords
- ortho
- preparation
- bicyclic heteroaryl
- matrix metalloproteinase
- hydroxamic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73200496A | 1996-10-16 | 1996-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA979235B true ZA979235B (en) | 1999-04-15 |
Family
ID=24941797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA979235A ZA979235B (en) | 1996-10-16 | 1997-10-15 | The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR009990A1 (en) |
| AU (1) | AU743901B2 (en) |
| WO (1) | WO1998016514A1 (en) |
| ZA (1) | ZA979235B (en) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548524B2 (en) * | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| WO1998016520A1 (en) * | 1996-10-16 | 1998-04-23 | American Cyanamid Company | The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| CN1138760C (en) * | 1997-10-06 | 2004-02-18 | 惠氏控股公司 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| EP1147085B1 (en) | 1999-01-27 | 2005-11-16 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors |
| US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| AR035311A1 (en) * | 1999-01-27 | 2004-05-12 | Wyeth Corp | HYDROXAMIC ACID DERIVATIVES CONTAINING ALQUINYL, AS INHIBITORS OF THE METALLOPROTEINAS OF MATRIX AND THE TACE, PHARMACEUTICAL COMPOSITION AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| AR022424A1 (en) * | 1999-01-27 | 2002-09-04 | American Cyanamid Co | COMPOUNDS DERIVED FROM ACIDS ORTOSULFONAMIDO ACETYLENE AND HYDROXAMIC HYDROXAMIC HYDROARAMYL AMID OF PHOSPHINIC ACID AS INHIBITORS TACE, COMPOSITION PHARMACEUTICAL THAT UNDERSTANDS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICATION |
| US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
| US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| KR20020079882A (en) * | 2000-02-21 | 2002-10-19 | 아스트라제네카 아베 | Arylpiperazines and Arylpiperidines and Their Use as Metalloproteinase Inhibiting Agents |
| CA2396965C (en) | 2000-02-21 | 2010-03-16 | Astrazeneca Ab | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
| AR027943A1 (en) * | 2000-02-25 | 2003-04-16 | Wyeth Corp | ARIL HYDROXAMIC ORTO-SULPHONAMIDE ACIDS AS MATRIX METALOPROTEINASE INHIBITORS AND PREPARATION OF THE SAME |
| AU2001250571A1 (en) * | 2000-04-28 | 2001-11-12 | P.N. Gerolymatos S.A. | Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol |
| US6576644B2 (en) | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
| US6436629B1 (en) * | 2000-10-27 | 2002-08-20 | The Regents Of The University Of California | Modulating angiogenesis |
| GB0119474D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| WO2003032999A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| EP1442018A1 (en) * | 2001-10-31 | 2004-08-04 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Novel anticancer compounds |
| BR0213736A (en) | 2001-11-01 | 2004-10-19 | Wyeth Corp | allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| CA2494048A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| US7098241B2 (en) | 2002-12-16 | 2006-08-29 | Hoffmann-La Roche Inc. | Thiophene hydroxamic acid derivatives |
| WO2005021489A2 (en) | 2002-12-23 | 2005-03-10 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
| US20080207673A1 (en) * | 2005-05-04 | 2008-08-28 | Michel Xilinas | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins |
| JP5588339B2 (en) * | 2007-06-25 | 2014-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | New chemical compounds |
| JP2012513464A (en) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Phosphodiesterase inhibitors and uses thereof |
| FR2947268B1 (en) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | NOVEL BENZENE-SULFONAMIDE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS |
| FR2947270B1 (en) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | NOVEL BENZENE-SULFONAMIDE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS |
| US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
| IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Anti amphiregulin antibodies, compositions comprising same and uses thereof |
| WO2017117130A1 (en) | 2015-12-28 | 2017-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
| EP3199534B1 (en) | 2016-02-01 | 2018-09-05 | Galderma Research & Development | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics |
| US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| WO1998016520A1 (en) * | 1996-10-16 | 1998-04-23 | American Cyanamid Company | The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
-
1997
- 1997-10-08 AU AU49806/97A patent/AU743901B2/en not_active Ceased
- 1997-10-08 WO PCT/US1997/018281 patent/WO1998016514A1/en active Application Filing
- 1997-10-15 ZA ZA979235A patent/ZA979235B/en unknown
- 1997-10-15 AR ARP970104749A patent/AR009990A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR009990A1 (en) | 2000-05-17 |
| WO1998016514A1 (en) | 1998-04-23 |
| AU743901B2 (en) | 2002-02-07 |
| AU4980697A (en) | 1998-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA979235B (en) | The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | |
| AU4756097A (en) | The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | |
| ZA979233B (en) | The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | |
| ZA979236B (en) | The preparation and use of ß-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors. | |
| PL333505A1 (en) | Benzamido-aldehydes and their application as inhibitors of cysteinic proteases | |
| AU4806097A (en) | Heteroaryl succinamides and their use as metalloproteinase inhibitors | |
| PL323710A1 (en) | Reversible inhibitors of cysteinic protease | |
| PL331254A1 (en) | Phosphonianic inhibitors of matrix metaloproteases | |
| AP9701054A0 (en) | Inhibitors of cycteine protease | |
| AU5493598A (en) | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases | |
| PL333434A1 (en) | Aminoguanidines and alkoxyguanidines as inhibitors of proteases | |
| AU9021498A (en) | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | |
| IL130300A0 (en) | Inhibitors of the enzymatic activity of PSA | |
| PL328665A1 (en) | Inhibitors of serinic protease | |
| AU3107795A (en) | Inhibitors of the benzamidine type | |
| HUP9904165A3 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof | |
| HUP0003880A3 (en) | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors, pharmaceutical compositions thereof and process for the preparation of the same | |
| IL115995A0 (en) | Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors | |
| GB9502858D0 (en) | Novel use of matrix metalloproteinase inhibitors | |
| AU5226798A (en) | Use of paracetamol as depigmenting agent | |
| AU7688998A (en) | Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema | |
| GB9708133D0 (en) | Novel use of matrix metalloproteinase inhibitors | |
| GB2239455B (en) | Formulations of lipolytic enzyme inhibitors and use of said inhibitors | |
| AU1836800A (en) | Amidomalonamides and their use as inhibitors of matrix metalloproteinase | |
| GB9405905D0 (en) | Inhibitors of isoprenylated protein endoprotease |